The type I interferon (IFN) response is an important component of the innate immune 43 response to viral infection. Precise control of interferon responses is critical, as insufficient 44 levels of interferon-stimulated genes (ISGs) can lead to a failure to restrict viral spread, 45 while excessive ISG activation results in interferon-related pathologies. While both 46 positive and negative regulatory factors can control the magnitude and duration of IFN 47
signaling, it is also appreciated that a number of ISGs regulate aspects of the interferon 48 response themselves. However, the mechanisms underlying complex ISG regulatory 49 networks remain incompletely defined. In this study, we performed a CRISPR activation 50 screen to identify new regulators of type I IFN responses. We identified ETS variant 51 transcription factor 7 (ETV7), a strongly induced ISG, as a protein that acts as a negative 52 regulator of the type I IFN response; however, ETV7 did not uniformly suppress ISG 53 transcription. Instead, ETV7 specifically targeted a subset of ISGs for regulation based 54 on their promoter sequences. We further showed the subset of ETV7-modulated ISGs is 55 particularly important for control of influenza viruses. Together, our data demonstrate that 56 ETV7 is a component of the complex ISG regulatory network by controlling the expression 57 of a subset of ISGs with a potential role in directing the interferon response against 58 specific viruses. 59
Introduction 71
The type I interferon (IFN) response is a transient innate immune defense system that, 72 upon activation by viral infection, induces the transcription of hundreds of interferon-73 stimulated genes (ISGs) (1). Many ISGs have characterized antiviral roles that restrict 74 viral replication by either interfering with viral processes directly or regulating the cellular 75 pathways required for viral replication (2). However, because replication mechanisms and 76 points of interaction with the cell differ between viruses, individual ISGs have varying 77 potencies against different viruses (3-5). As a result, unique combinations of ISGs are 78 thought to mediate successful antiviral responses against distinct viruses (1, 6) . 79
80
The activation of the type I IFN signaling pathway in response to viral infection is well 81 understood (7, 8). Extracellular IFN, which is released after a cell recognizes virus-derived 82 nucleic acid, is bound by its cognate plasma membrane-localized receptor (IFNARs). 83
Downstream effectors (JAK proteins) are phosphorylated to then activate interferon-84 stimulated gene factor 3 (ISGF3) complex formation. Finally, the ISGF3 complex of 85 STAT1, STAT2, and IRF9 translocates to the nucleus (7). There, ISGF3 binds the 86 interferon sensitive response element (ISRE), with the consensus DNA motif 87 GAAANNGAAA, to activate transcription of ISGs (9). 88 89 As infection is cleared and virally derived innate immune activators become scarce, 90 interferon production is reduced and the interferon-stimulated gene response is 91 downregulated. To facilitate this return to cell homeostasis, negative regulators are 92 induced and act at multiple levels in the signaling pathway (10). For example, PKD2 is an 93 ISG that recruits ubiquitin to the IFN receptor, IFNAR1, resulting in its degradation (11) . 94 SOCS1 and SOCS3 are upregulated during, and act to limit, the IFN response through 95 direct interactions with JAK proteins, while SOCS1 also ubiquitinates other pathway 96 components (12). USP18 is induced by IFN to help return the cell to homeostasis by 97 removing the ubiquitin-like ISG15 from target proteins (13). Thus, negative regulators of 98 IFN responses are an important group of IFN-stimulated genes that control the duration 99 of ISG induction and activity. 100 101 In addition to activating or suppressing IFN responses, there are a number of interferon-102 induced regulators that enhance, limit, or fine-tune antiviral activity (14). Many ISGs 103 themselves participate in innate immune signaling to amplify IFN, and other pro-immune, 104 responses. For example, IFN signaling increases the levels of STAT1/2 and IRF9, thus 105 forming a positive feedback loop that enhances further ISG expression (15). Activators 106 also add complexity by inducing non-canonical IFN response pathways or specific groups 107 of ISGs. Interferon responsive factors (IRFs) 1 and 7 are ISGs and transcription factors 108 that activate subsets of ISGs (16, 17) . Recent work has shown ELF1 (E74-like ETS 109 transcription factor) is induced by IFN, resulting in the expression of a group of genes not 110 otherwise activated by the IFN response (18). These differential ISG profiles are thought 111 to allow the cell to fine-tune its antiviral activity for an effective and appropriate response. 112
While interferon-induced positive regulators of the IFN response are known to shape the 113 complexity of ISG activation, reports of analogous roles for negative regulators remain 114 conspicuously absent. 115
116
To address this gap in knowledge and identify genes able to shape the IFN response 117 through negative regulation, we performed a CRISPR activation (CRISPRa) screen that 118 selected for factors sufficient to prevent expression of an ISRE-containing IFN response 119 reporter. We identified ETV7 (ETS variant transcription factor 7) as a negative regulator 120 of the type I IFN response with a role in controlling the expression of a subset of ISGs. 121
We further showed the ETV7-modulated ISGs are important for control of influenza 122 viruses. Together, these data demonstrate ETV7 is a suppressive component of the 123 complex ISG regulatory network that could be targeted to enhance specific antiviral 124 responses against influenza viruses (1, 19) . 125
126

Results
127
A CRISPR activation screen identifies potential negative regulators of the type I IFN 128
response. 129
In order to identify negative regulators of the type I IFN response, we developed a type I 130 IFN response reporter (IFNrsp) that included seven copies of the consensus interferon 131 sensitive response element (ISRE) ahead of a minimal CMV promoter controlling 132 expression of sfGFP ( Fig. 1A) . To make our reporter temporally specific, sfGFP was 133 fused to a mouse ornithine decarboxylase (MODC) protein degradation domain to 134 decrease its half-life (20). We stably introduced this construct into the A549 lung epithelial 135 cell line along with a dCAS9-VP64 fusion protein and a MS2-p65-HSF1 activator complex 136 required for the SAM CRISPR activation system (21). After clonal selection, 99.8% of the 137 A549-SAM-IFNrsp cells expressed GFP in response to type I IFN treatment ( Fig. 1B and  138 C). To perform the screen, we took the A549-SAM-IFNrsp cell line and transduced 2×10 8 139 cells at a multiplicity of infection (MOI) of 0.5 with a lentivirus library containing sgRNAs 140 designed to activate every putative ORF in the human genome (21) (Fig. 1D) . After 48 141 hours, half of the cells were collected to determine the transduction efficiency and the 142 remaining cells were re-plated for IFN stimulation. At 72 hours post-sgRNA introduction, 143
Fig. 1. A CRISPR activation screen to identify negative regulators of the type I interferon response.
A) Diagram of the IFN response reporter (IFNrsp) used to identify cells responding to IFN. ISRE = interferon sensitive response element, MODC = protein degradation domain. B) Flow cytometry histogram and C) bar graph of A549-SAM-IFNrsp cells before and after IFN-α treatment (1000 U/mL, 6 h) (data shown as mean ± SD, n=4). Data shown are representative of two independent experiments. P-values calculated using unpaired, two-tailed Student's t-tests, *p<0.05, **p<0.001. D) Diagram of CRISPRa screen workflow to identify negative regulators of the type I IFN response. E) Results of the two independent CRISPRa screens. Z-score values from the replicate screens with a cutoff of 2 standard deviations from the mean were used to identify top "hits". F) Venn diagram indicating overlapping hits from the replicate screens and genes upregulated by interferon at least two-fold, according to the Interferome database (23). the cells were treated with 4,000 U/mL IFN-a for 6 hours and collected for fluorescence-144 activated cell sorting. During sorting, we eliminated reporter-positive cells and collected 145 only cells that were nonresponsive to IFN, because this population should theoretically 146 be overexpressing a negative regulator of the IFN response. We performed two 147 independent biological replicates of the screen and sequenced the sgRNA-containing 148 amplicons derived from our input DNA, unselected transduced cells, and cells that were 149 nonresponsive to type I IFN. Raw sequencing data was aligned and mapped and 150 subsequently analyzed using the MAGeCK pipeline (22) to generate z-score values for 151 each gene. Genes were defined as "hits" if their z-scores exceeded two standard 152 deviations from the mean, resulting in an overlap of 10 genes between the two screen 153 replicates ( Fig. 1E, Supplementary Data 1 Table 1 ). We 154 were seeking to identify regulators of the IFN response that are regulated by IFN 155 themselves; therefore, we selected hits for validation previously reported to have at least 156 a two-fold induction after IFN stimulation in the Interferome database (23). This analysis 157 identified three hits (C1GALT1, ETV7, and NUP153) as potential negative regulators of 158 the type I IFN response ( Fig. 1F and Supplementary Table 1 ). 159
and 2, and Supplementary
160
Overexpression of ETV7 is sufficient to negatively regulate the type I IFN response. 161
To validate our three hits, and to avoid potential false positive results as the result of off-162 target effects of CRISPRa, we cloned the three ORFs and validated overexpression of 163 the genes in 293T cells (Supplementary Figure 1) . Co-transfection of the 164 overexpression plasmids and IFNrsp plasmid, followed by stimulation with IFN-a, resulted 165 in significantly fewer GFP-expressing cells compared to a control mCherry-expressing 166 plasmid ( Fig. 2A and B) . To verify this repressive activity was specific to the IFN response 167 and the hits were not general inhibitors of transcription or translation, we transfected the 168 overexpression plasmids along with a constitutively active GFP-expressing plasmid ( Fig.  169   2C) . We included a positive control (EIF2AK1/HRI), which is known to shut off translation 170 when overexpressed (24). C1GALT1 overexpression significantly downregulated GFP 171 expression, indicating the repressive activity of C1GALT1 is not completely specific to the 172 IFN response. While the overexpression of either ETV7 or NUP153 specifically affected 173 the IFNrsp plasmid, NUP153 has previously been shown to control the distribution of 174 STAT1 in the cell (25). We therefore chose ETV7 for further characterization because: 1) 175 ETV7 had not been previously reported to play a role in the IFN response, and 2) it had 176 the strongest inhibitory phenotype against the IFNrsp reporter. 177
178
After confirming overexpression of ETV7 at the protein level ( Fig. 2D) , we verified the 179 inhibitory effects of ETV7 were not restricted to the reporter plasmid. We collected mRNA 180 and protein from IFN-a stimulated ETV7 overexpression cells to quantify effects on the 181 expression of endogenous ISGs. ETV7 overexpression significantly repressed the 182 induction of three prototypical ISGs (IFIT1, MX1, and ISG15) at the RNA level ( Fig. 2E) . 183
The reduction of ISG expression during ETV7 overexpression was also demonstrated at 184 the protein level for IFIT1 ( Fig. 2F) . These experiments show that overexpression of ETV7 185 is sufficient to repress ISG induction by type I IFN. 186 187
Fig. 2. ETV7 overexpression suppresses ISG expression. A) Flow cytometry plots of 293T cells transfected with the IFNrsp reporter and overexpression plasmids for the indicated screen hits then treated with IFN-α (100 U/mL, 6 h). B) Quantification of A
showing normalized percentage of cells expressing GFP compared to the mCherryexpressing control (data shown as mean ± SD, n=4). C) Normalized percentage of cells expressing GFP from a constitutively expressing plasmid in cells overexpressing the indicated genes (positive control = EIF2AK1/HRI, shuts off translation) compared to control (data shown as mean ± SD, n=4). D) Western blot showing ETV7 protein levels in 293T cells transfected with the ETV7 overexpression plasmid. Stain-free gel imaging was used to confirm equal loading. E) Endogenous ISG mRNA expression levels measured using RT-qPCR after IFN-α treatment (100 U/mL, 9 h) (data shown as mean ± SD, n=4). F) Western blot comparing IFIT1 protein levels in control and ETV7 overexpressing cells after IFN-α treatment (500 U/mL, 18 h). ns = nonspecific band. Stainfree gel imaging was used to confirm equal loading. For all panels: Data shown are representative of two independent experiments. P-values calculated using unpaired, twotailed Student's t-tests (*p<0.05, **p<0.001) compared to IFN-stimulated, mCherryexpressing control samples.
ETV7 acts as a transcription factor to repress the type I IFN response. 189
ETV7 is known to be a repressive transcription factor (26, 27), although a role in 190 repressing type I IFN responses has never been reported. To determine whether ETV7 191 acts as a transcription factor in this context, we generated a previously validated mutant 192 of ETV7, called ETV7(KALK), which is unable to bind DNA ( Fig. 3A and B) (28) . 193
Overexpression of ETV7(KALK) and stimulation with IFN-a had no measurable effect on 194 expression of the IFNrsp reporter, in contrast to WT ETV7 overexpression ( Fig. 3C) . 195 196 ETV7 has been reported to bind the canonical ETS family DNA motif, GGAA (29), known 197
as an "ETS" site ( Fig. 3D ). Since consensus ISREs can either contain or lack a GGAA 198 motif ( Supplementary Table 2 ), we hypothesized ETV7 could act on specific ISGs based 199 on the presence of ETS sites in their promoters. The original IFN response reporter design 200 contained multiple ETS sites ( Fig. 3E) , which potentially explains why it is negatively 201 impacted by ETV7. To test the requirements of ETS sites for ETV7 repressive activity, we 202 generated an IFN response reporter containing seven consensus ISREs from canonical 203
ISGs that all lack ETS sites (ISRE -ETS) ( Fig. 3E) . We transfected the two reporter 204 plasmids (ISRE +ETS and ISRE -ETS) independently into 293T cells and stimulated with 205 IFN-a. As expected, both reporter plasmids responded to IFN treatment, but the 206 repressive activity of ETV7 was restricted to the reporter plasmid containing ETS motifs 207 ( Fig. 3F) . These experiments together demonstrate that ETV7's repressive activity 208 requires both its ability to bind DNA and the presence of ETS sites in ISG promoters. 209 210 ETV7 differentially regulates genes based on their ISRE sequence. 211
Our data suggested ETV7 likely does not affect all ISG promoters. To perform an 212 unbiased examination of ETV7's repressive activity against ISGs with a variety of 213 potential regulatory sites, we performed RNA sequencing in cells with or without ETV7 214 Data 3) . We then generated a 215 dendrogram using the 2,000 most differentially expressed genes after IFN treatment to 216 compare the four conditions: overexpression of control protein (mCherry) or ETV7, and 217 with or without IFN-a treatment. When comparing the impact of IFN treatment on control 218 and ETV7-overexpressing cells, we observed a larger divergence in the transcriptional 219 profile of control cells compared to ETV7-overexpressing cells after IFN treatment ( Fig.  220   4A) . This difference demonstrates that ETV7 generally "dampens" the transcriptional 221 impact of IFN treatment. Using a heat map to observe patterns in genes that increased 222 at least two-fold upon IFN treatment, we found some genes are more suppressed during 223 ETV7 overexpression than others ( Fig. 4B) . We divided these genes into three groups 224 (from I = most affected to III = least affected) depending on their response to ETV7 225 overexpression and we examined their promoters to identify motifs associated with ETS 226 transcription factors and IFN regulation. Unexpectedly, comparing the number of ETS 227 binding sites (GGAA) across these three groups revealed no significant difference 228 between the differentially affected groups (Fig. 4C) . However, it is known that ETS sites 229 sometimes occur as a part of combined motif related to ISREs, known as ETS-IRF 230 combined elements (EICEs) with the consensus sequence GGAANN(N)GAAA (30, 31). 231
overexpression and IFN stimulation (Supplementary
We therefore tested the hypothesis that ETV7 negatively regulates ISGs with EICE sites. 232
The number of EICE sites was significantly different between the most and least ETV7-233 affected groups (Fig. 4D) , indicating ETV7 impacts the expression of specific ISGs by 234 targeting an extended DNA binding motif. ETV7 is required to negatively regulate specific ISGs. 240
Our experiments to this point used an overexpression system to demonstrate that ETV7 241 is sufficient to suppress ISG expression. However, this approach leads to constitutive 242 ETV7 expression at high levels relative to the physiological magnitude and IFN-induced 243 expression of ETV7 (Fig. 5A) . To determine the importance of ETV7 induction during the 244 IFN response, we performed a series of loss of function experiments that we expected 245 would have the reciprocal effect on IFN responses (32). We transduced A549-IFNrsp 246 reporter cells (the original reporter with ISRE +ETS sites) with Cas9 and one of two 247 different sgRNAs targeting ETV7 (ETV7 KO1, ETV7 KO2), selected for edited cells, and 248 then stimulated with IFN-a. Both guides resulted in significantly more IFN-induced sfGFP 249 expression compared to a control sgRNA (Fig. 5B) . We next generated clonal ETV7 250 knockout A549 lung epithelial cell lines and sequenced the resulting DNA lesions to 251 confirm ETV7 knockout (Supplementary Figure 2) . Since ETV7 is normally only 252 expressed after IFN stimulation, we treated with IFN-a and verified a reduction in ETV7 253 expression at the RNA level ( Fig. 5C) . We then selected five ISGs for RT-qPCR analysis. 254
Three (IFI44L, RSAD2/Viperin, IFIT3) were from the group most affected by ETV7 (Group 255 I) that contained multiple EICEs in their promoters. Two (IFIT5, IRF9) were chosen from 256 the less affected groups (Groups II and III). The EICE-rich genes (Group I) showed 257 significantly higher levels of RNA expression in the ETV7 knockout cells (Fig. 5D) , while 258 genes with few EICEs were not significantly impacted by the loss of ETV7 (Fig. 5E) . Thus, 259 the physiological level of ETV7 induction after IFN stimulation affects the expression of a 260 subset of ISGs. 261
Loss of ETV7 restricts influenza viral replication. 263
For a successful antiviral response, individual ISGs are thought to work together to restrict 264 multiple parts of the virus replication cycle (1). To determine whether the effects of ETV7 265
Fig. 5. ETV7 loss enhances expression of specific ISGs.
A) ISG15 and ETV7 mRNA levels in A549 lung epithelial cells after IFN-α treatment (1000 U/mL, 6 h) (data shown as mean ± SD, n=4). B) Percentage of A549 cells expressing GFP from IFNrsp reporter after knockout of ETV7 and IFN-α treatment (1000 U/mL, 6 h) (data shown as mean ± SD, n=3, statistical analysis represents p-values for both of the two ETV7 KO sgRNAs compared to a non-targeting control). C) mRNA levels of ETV7 in non-targeting control and ETV7 KO A549 cells after IFN-α treatment (1000 U/mL, 6 h) (data shown as mean ± SD, n=4). D,E) Representative genes were chosen from the groups D) most affected by ETV7 (Group I) and E) least affected (Groups II and III) in the RNA sequencing analysis (Fig. 4B) . Each gene's potential ISRE sequences (ETS sites highlighted in yellow) are shown, along with its mRNA levels in control and ETV7 KO cells after IFN-α treatment (1000 U/mL, 6 h) (data shown as mean ± SD, n=4). For all panels: Data shown are representative of two independent experiments. P-values calculated using unpaired, twotailed Student's t-tests (*p<0.05, **p<0.001) compared to IFN-stimulated, non-targeting sgRNA control samples unless otherwise indicated. suppression of ISG expression were relevant in the context of a viral infection, we wanted 266 to identify a virus restricted by the genes regulated by ETV7 (i.e. Group I genes) (33). 267
Considering the Group I genes with well recognized antiviral functions (IFITM1, IFIT1-3, 268 OAS1-3, BST2, RSAD2), we found each had been reported to play important roles in the 269 To determine whether ETV7 regulation affected influenza virus infection, we first infected 275
our ETV7 knockout A549 cells with a laboratory-adapted H1N1 influenza A virus (IAV), 276
A/Puerto Rico/8/1934 (PR8). Using a hemagglutination (HA) assay to measure the 277 number of viral particles released over time, we observed reduced virus production in our 278 ETV7 KO cells compared to control cells (Fig. 6A) . This was the anticipated outcome 279 because loss of a negative regulator (i.e. ETV7) is expected to enhance expression of 280 antiviral ISGs. We also measured infectious viral titers and found a significant reduction 281 in our ETV7 KO cells compared to control cells (Fig. 6B) . Using a fluorescent reporter 282 strain of PR8 (PR8-mNeon) (40), we next visualized infection and spread. As expected, 283
we observed fewer cells expressing mNeon in ETV7 KO cells using both microscopy (Fig.  284   6C) and flow cytometry readouts (Fig. 6D ). Next, we tested whether ETV7's impact on 285 influenza virus infection and spread would extend to a more contemporary H1N1 IAV cells when comparing ETV7 KO cells to control cells ( Fig. 6E and F) . These experiments 290 demonstrate that loss of ETV7 leads to decreased viral replication across multiple, 291 unrelated influenza viruses. 292 
Discussion 293
In this study, we performed a CRISPR activation screen to identify negative regulators of 294 the type I IFN response. Specifically, we were interested in negative regulators that 295 contribute to the types of differentiated ISG profiles IFN-induced activators are reported 296 to produce. From this screen, we identified ETV7 as a negative IFN regulator and showed 297 it acts as a transcription factor to repress subsets of ISGs dependent on a motif related 298 to the ISRE, the EICE. We also showed ETV7's regulatory activity impacts the replication 299 and spread of multiple strains of influenza viruses. These findings demonstrate the 300 importance of ETV7 in fine-tuning the IFN response through specificity and transcriptional 301 repression to regulate particular, antiviral ISG targets. 302 303 ETV7 is a member of the ETS family of transcription factors. This family performs diverse 304 functions despite recognizing the same core DNA sequence, GGAA, by acting on 305 extended motifs requiring binding partners (42, 43) . In our work we identified the EICE, a 306 recognized ETS transcription factor-associated motif, as a regulatory element related to 307
ISREs that ETV7 uses to discriminate genes for regulation. The EICE has previously been 308 reported to require an IRF binding partner to direct ETS transcription factor activity (30, 309 31); therefore, it is likely ETV7 has an IRF binding partner. If ETV7 does require a binding 310 partner, this protein's induction and distribution likely contribute to the timing, gene 311 targets, and activity of ETV7 during the IFN response. It is known that IRFs can be basally to the temporal regulation of specific waves of ISGs (45). These coordinated waves of 320 ISG induction can peak early or late during the IFN response and are thought to 321 correspond to specific stages of virus replication or immune processes (1, 6). We 322 compared the induction of ETV7 and ISG15 and observed ETV7 is both upregulated and 323 downregulated at earlier time points than this prototypical ISG (Fig. 5A) . We expanded 324 our analysis to published datasets of human gene expression during respiratory infections 325 and concluded that ETV7 is generally induced earlier than many ISGs (46). Although not 326 the focus of our study, ETV7's early and short induction pattern suggests it may be a key 327 regulator of the first stages of IFN-mediated gene induction. We favor a model wherein 328 early ETV7 expression is responsible for reducing the accumulation, or delaying the 329 expression, of ISGs controlled by EICE motifs (Supplementary Fig. 3) . 330 331 ETV7 is induced during infections across many vertebrate species (47, 48), indicating a 332 potential conserved, relevant role in the immune response; however, ETV7 has been lost 333 in mice and closely related rodents (49). Since mice and rodents have an intact interferon 334 response pathway, a natural question is: how are the activities of ETV7 being accounted 335 for in these animals? While we have no clear answer from the data in this study, it is well-336 recognized that IFN responses contains many redundancies (33). Accordingly, we believe 337 other ETS family members, potentially the closely related ETV6 (which is also induced by 338 IFNs), may perform the role of ETV7 in mice (50). Future studies will be required to test 339 the hypothesis that mice induce an ETV7-related alternative during the type I IFN 340
response. 341 342
Another important question is why ETV7's IFN-induced activity has been maintained 343 throughout evolution. In this report, we provide evidence that ETV7's activity reduces a 344 cell's ability to restrict influenza virus infection; this seems counterintuitive to ETV7 345 benefitting the host. We hypothesize that regulators like ETV7 are important to prevent 346 excessive inflammatory signaling. It is appreciated that negative regulators of the IFN 347 response are required to prevent extreme and prolonged immune responses, which are 348 associated with poor disease outcomes after infection (51-53). ETV7 potentially 349 contributes to the cumulative activities of negative IFN regulators to limit IFN responses 350 during pathogen clearance. Additionally, it stands to reason that different individual ISGs 351 have differing toxic effects on the cell. It is tempting to speculate that ETV7 suppresses 352
ISGs whose accumulation is particularly harmful to cell viability and host recovery after genome wide association studies (GWAS) have linked ETV7 to autoimmune diseases 363 including rheumatoid arthritis and multiple sclerosis (59, 60); both of these autoimmune 364 diseases have evidence of enhanced ISG expression (61, 62). Thus, although the specific 365 contributions of ETV7 activity to IFN regulation are currently undefined, its potential role 366
is not limited to viral infections. 367
368
In conclusion, we identified ETV7 as a negative regulator of the type I IFN response. 369
Previously, ETV7 was appreciated to be an ISG; however, a specific function during the 370 IFN response was unknown. We determined that ETV7 acts as a transcription factor to 371 target specific ISGs for repression, potentially contributing to the complex ISG 372 transcriptional landscape. Additionally, many of the ETV7-modulated ISGs restrict 373 influenza viruses (34) and we showed that loss of ETV7 limits influenza virus spread. 374
Further work is required to understand the complexity of IFN regulation, while therapeutic 375 targeting of factors like ETV7 could lead to the development of a new class of host-376 directed antivirals that tailor ISG responses to specific viruses. 377
Experimental Procedures 378
Cloning 379
To generate reporters sensitive to IFN, we designed gBlocks (IDT) containing ISREs to 380 be cloned into the pTRIP vector ahead of a minimal CMV promoter controlling expression 381 of sfGFP. To clone and express the open reading frames (ORFs) of our screen hits, we 382 designed primers for cloning into the pLEX-MCS vector using Gibson Assembly (NEB). 383
To amplify ETV7 and NUP153, we used cDNA templates from Transomic Technologies. 384
To amplify C1GALT1 and EIF2AK1, we used RNA from IFN-stimulated A549 cells. The 385 DNA binding mutant, ETV7(KALK) (28), was also generated using a gBlock. Non-386 targeting and ETV7-targeting CRISPR KO sgRNAs were cloned by annealing oligos 387 encoding the desired sgRNA sequence and ligating them directly into the lentiCRISPRv2 388 vector (Addgene). DNA was transformed into NEB 5-alpha high efficiency competent 389 cells. Insert size was verified with PCR and purified plasmids were sequenced using 390 Sanger sequencing. 391 392
Cells 393
All cells were obtained from ATCC and grown at 37°C in 5% CO2. A549 and 293T cells 394
were grown in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 5% fetal 395 bovine serum, GlutaMAX, and penicillin-streptomycin. Madin-Darby canine kidney 396 (MDCK) cells were grown in minimal essential media (MEM) supplemented with 5% fetal 397 bovine serum, HEPES, NaHCO3, GlutaMAX, and penicillin-streptomycin. The A549 398 CRISPR-SAM cells were previously validated (63) and transduced with the IFNrsp 399 reporter three times before being clonally selected. The A549 CRISPR KO cells were 400 transduced and then selected using puromycin (10 µg/mL). 401 402
Flow Cytometry 403
Cells were trypsinized and analyzed on a Fortessa X-20 (BD) machine with standard laser 404 and filter combinations. Data was visualized and processed with FlowJo software. 405
406
CRISPR Activation Screen 407
The sgRNA library was packaged into lentivirus as previously described (63). After 408 packaging and titering the lentivirus, 2x10 8 A549-CRISPR-SAM-IFNresp cells were 409 seeded onto 15 cm plates (10 plates total). The next day they were transduced with the 410 packaged sgRNA library (MOI=0.5). After 48 h, the transduced cells were split and half 411 were collected as a transduction control, while the remaining half were plated back onto 412 15 cm plates. The next day, cells were treated with IFN-a (4x10 3 U/mL) for 6 h. Cells were 413 then collected and sorted on a Beckman Coulter Astrios cell sorter. Specifically, gates 414 were set to sort GFP-negative cells as the population of interest, as well as GFP-positive 415 cells as a control population of cells still capable of signaling. This screen was performed 416 in duplicate. Genomic DNA was extracted from sorted cells using the Zymo Quick gDNA 417 micro prep kit. PCR was subsequently performed using barcoded primers as previously 418 described using the NEB Next High Fidelity 2x PCR master mix (63). PCR bands were 419 gel purified using the Thermo GeneJET gel extraction kit. Samples were then sequenced 420 via next-generation Illumina MiSeq using paired-end 150 bp reads. 421
422
Screen Analysis 423
Raw MiSeq read files were aligned to the CRISPR SAM sgRNA library and raw reads for 424 each sgRNA were counted using the MAGeCK pipeline (22). sgRNA enrichment was 425 determined using the generated count files and the MAGeCK-MLE analysis pipeline. 426
Genes were sorted based on z-score and determined to be significantly enriched if their 427 z-score was at least two standard deviations above the average z-score of the entire 428 sorted population. 429 430
Western Blotting 431
Cells were trypsinized and 1x10 6 cells were pelleted at 800 x g for 5 min. Equal amounts 432 of cellular material were loaded into 4-20% acrylamide gels (Bio-Rad) and imaged using 433 a ChemiDoc Imaging System (Bio-Rad). Protein was transferred to a nitrocellulose 434 membrane at 60V for 60 min. PBS with 5% (w/v) non-fat dried milk and 0.1% Tween-20 435 were used to block for 1 h at 4°C. Primary antibodies were then incubated with the 436 membrane overnight at 4°C. Antibodies used were rabbit anti-ETV7 (Sigma, HPA029033) 437 and rabbit anti-IFIT1 (Cell Signaling, D2X9Z). Membranes were washed five times in PBS 438 with 0.1% Tween-20 and then an anti-rabbit-HRP secondary antibody (Thermo, A16104) 439 was added for 1 h. The membrane was then washed five times and Clarity or Clarity Max 440 ECL substrate (Bio-Rad) was added before being exposed to film and developed. 441
442
RT-qPCR 443
Total RNA was collected using Monarch Total RNA Miniprep Kits (NEB). One-step RT- Hemagglutination (HA) assays to measure the amount of viral particles were performed 484 by diluting influenza infected cell supernatants collected at the indicated time points in 485 cold PBS. An equal amount of chicken blood diluted 1:40 in PBS was mixed with serially 486 diluted virus and incubated at 4°C for 2-3 h before scoring. Infectious viral titers were 487 determined using standard plaque assay procedures on MDCK cells. Infected cell 488 supernatants were collected at 18 h, serially diluted, and used to infect confluent 6-well 489 plates for 1 h before removing the virus and adding the agar overlay. Cells were then 490 incubated at 37°C for 48 h before being fixed in 4% PFA overnight. The 4% PFA was then 491 aspirated, and the agar layer was removed before washing cells with PBS. Serum from 492 WT PR8 infected mice was diluted 1:2,000 in antibody dilution buffer (5% (w/v) non-fat 493 dried milk and 0.05% Tween-20 in PBS) and incubated on cells at 4°C overnight. Cells 494 were then washed twice with PBS and incubated for 1 h with anti-mouse IgG horseradish 495 peroxidase (HRP)-conjugated sheep antibody (GE Healthcare) diluted 1:4,000 in 496 antibody dilution buffer. Assays were then washed twice with PBS and exposed to 0.5 mL 497 of TrueBlue peroxidase substrate (KPL) for 20 min. Plates were then washed with water 498 and dried before plaques were counted. 499 500
Data Availability 501
All next generation sequencing data are available at NCBI GEO under accession number 502 GSE140718. 503 504 505
